Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
Posted inHematology-Oncology news Oncology

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and encouraging early survival outcomes.